Guidant Corporation Initiates SPIRIT III Clinical Trial for XIENCE V Drug Eluting Stent System

The Guidant Corporation, a leader in the development of vascular stent systems, has commenced enrollment in its large-scale SPIRIT III clinical trial for the XIENCE V drug eluting stent system. This prospective, randomized, single-blind trial aims to evaluate the safety and efficacy of XIENCE V in comparison to the TAXUS Express 2 Paclitaxel Eluting Coronary Stent System for the treatment of coronary artery disease. The SPIRIT III trial is a crucial step towards obtaining FDA approval for XIENCE V, which has the potential to offer a new therapy for physicians and patients worldwide.

Key Takeaways:

The SPIRIT III clinical trial evaluates the safety and efficacy of XIENCE V, an everolimus eluting coronary stent system, compared to the TAXUS Express 2 Paclitaxel Eluting Coronary Stent System.
The trial is a prospective, randomized, single-blind study, involving the enrollment of patients with coronary artery disease.
The trial is being conducted at several prominent medical centers, including Brigham and Women's Hospital, St. Joseph's Medical Center, and Wake Forest University Baptist Medical Center.
Gregg Stone, MD, and Campbell Rogers, MD, are co-principal investigators of the study.
Guidant also anticipates initiating the SPIRIT II clinical trial in Europe in the near future.

Statistics:

The SPIRIT III trial is a large-scale pivotal clinical trial evaluating the XIENCE V drug eluting stent system.
The trial aims to enroll a significant number of patients, although the exact number is not specified in the provided text.
The trial is expected to provide valuable insights into the safety and efficacy of XIENCE V for the treatment of coronary artery disease.

Sources:

Guidant Corporation

Health & Medicine Week editors